FinCanna Capital Past Earnings Performance
Past criteria checks 0/6
FinCanna Capital's earnings have been declining at an average annual rate of -2%, while the Pharmaceuticals industry saw earnings growing at 26.2% annually. Revenues have been declining at an average rate of 52.4% per year.
Key information
-2.0%
Earnings growth rate
10.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | -52.4% |
| Return on equity | n/a |
| Net Margin | 76.4% |
| Last Earnings Update | 31 Jan 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How FinCanna Capital makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Jan 24 | -1 | 0 | 0 | 0 |
| 31 Oct 23 | -1 | -1 | 0 | 0 |
| 31 Jul 23 | -1 | -1 | 0 | 0 |
| 30 Apr 23 | -2 | -2 | 0 | 0 |
| 31 Jan 23 | -4 | -9 | 1 | 0 |
| 31 Oct 22 | -4 | -9 | 1 | 0 |
| 31 Jul 22 | -4 | -9 | 1 | 0 |
| 30 Apr 22 | -3 | -9 | 2 | 0 |
| 31 Jan 22 | -1 | -12 | 2 | 0 |
| 31 Oct 21 | -1 | -12 | 3 | 0 |
| 31 Jul 21 | -1 | -12 | 2 | 0 |
| 30 Apr 21 | -1 | -11 | 2 | 0 |
| 31 Jan 21 | -1 | -9 | 2 | 0 |
| 31 Oct 20 | -1 | -12 | 2 | 0 |
| 31 Jul 20 | 0 | -11 | 2 | 0 |
| 30 Apr 20 | 0 | -12 | 2 | 0 |
| 31 Jan 20 | 0 | -5 | 2 | 0 |
| 31 Oct 19 | 1 | -2 | 3 | 0 |
| 31 Jul 19 | 1 | 0 | 3 | 0 |
| 30 Apr 19 | 1 | 0 | 4 | 0 |
| 31 Jan 19 | 2 | 0 | 4 | 0 |
| 31 Oct 18 | 2 | -10 | 6 | 0 |
| 31 Jul 18 | 1 | -12 | 5 | 0 |
| 30 Apr 18 | 1 | -13 | 5 | 0 |
| 30 Apr 17 | 0 | -1 | 1 | 0 |
Quality Earnings: CALI.X is currently unprofitable.
Growing Profit Margin: CALI.X is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CALI.X is unprofitable, and losses have increased over the past 5 years at a rate of 2% per year.
Accelerating Growth: Unable to compare CALI.X's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CALI.X is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (18.4%).
Return on Equity
High ROE: CALI.X's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.